Related Experiment Video
Updated: Aug 19, 2025
07:11
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
Published on: May 23, 2025
328
Noncoding RNAs in Pulmonary Arterial Hypertension: Current Knowledge and Translational Perspectives
Nadia Bernardi1, Eva Bianconi2, Andrea Vecchi1
1Department of Internal Medicine, University of Genova, Viale Benedetto XV, 6, Genova 16132, Italy.
Heart Failure Clinics
|November 26, 2022
Summary
Noncoding RNAs (ncRNAs) play a role in pulmonary arterial hypertension (PAH) by affecting cell behavior and nitric oxide. Further research is needed to understand ncRNAs for PAH diagnosis and treatment.
Area of Science:
- Cardiovascular Biology
- Molecular Biology
- Genetics
Background:
- Pulmonary arterial hypertension (PAH) involves complex molecular mechanisms.
- Noncoding RNAs, including microRNAs and long noncoding RNAs, are implicated in PAH pathogenesis.
Purpose of the Study:
- To review the current understanding of noncoding RNAs (ncRNAs) in pulmonary arterial hypertension (PAH).
- To highlight the potential of ncRNAs as biomarkers and therapeutic targets for PAH.
Main Methods:
- Literature review of studies investigating ncRNAs in PAH.
- Analysis of ncRNA roles in smooth muscle cell proliferation, apoptosis, and endothelial-to-mesenchymal transition.
Main Results:
- ncRNAs impair nitric oxide production in PAH.
- ncRNAs enhance smooth muscle cell proliferation and migration while decreasing apoptosis.
- ncRNAs promote endothelial-to-mesenchymal transition in pulmonary arteries.
Conclusions:
- ncRNAs are significant contributors to PAH pathogenesis.
- ncRNAs hold promise as diagnostic biomarkers and therapeutic targets for PAH.
- Further research and technological advancements are required to translate ncRNA findings into clinical applications for PAH.
More Related Videos
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
261
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
261
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
231
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
231
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
215
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
215
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
244
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
244
02:39lncRNA - Long Non-coding RNAs
8.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
303
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
303